Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration?

In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor ...

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, ...
Nature

RAS cancer biology (mutations, signaling, etc.) plus emerging RAS-directed therapeutic advances and new horizons

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
The American Journal of Managed Care

Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...
EurekAlert!

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...